The latest news updates from the 2024 Symposium
-
New Translational Controversies session to feature ‘lightning discussions’ on important topics
Read More: New Translational Controversies session to feature ‘lightning discussions’ on important topicsKomal Jhaveri, MD, FACP, will moderate discussions about current controversies in translational medicine for breast cancer.
-
Panel to discuss approaches to managing moderate hereditary risk for breast cancer
Read More: Panel to discuss approaches to managing moderate hereditary risk for breast cancerSeema A. Khan, MD, will lead a session on Thursday afternoon looking at evolving evidence on managing patients at moderate genetic breast cancer risk.
-
Session will explore diagnostic and treatment challenges of less common breast cancer types
Read More: Session will explore diagnostic and treatment challenges of less common breast cancer typesAn educational session on Thursday, moderated by Bora Lim, MD, will explore the diagnosis and treatment of less common, more challenging, breast cancers.
-
Demystifying CDKs in Breast Cancer: Beyond CDK4/6: Presenter Profiles
Read More: Demystifying CDKs in Breast Cancer: Beyond CDK4/6: Presenter ProfilesAriella Hanker, PhD, and Sarat Chandarlapaty, MD, PhD, preview their presentations on inhibitors, set for Thursday afternoon.
-
Leading investigator in breast cancer genetics, disease progression, and research methodology named Brinker Awardee for Scientific Distinction in Basic Science
Read More: Leading investigator in breast cancer genetics, disease progression, and research methodology named Brinker Awardee for Scientific Distinction in Basic ScienceGeoffrey M. Wahl, PhD, will receive the Brinker Award for Scientific Distinction in Basic Science on Thursday, and will deliver the lecture “Guardian at the Gates: Genome Stability, Cell State, Plasticity, and Breast Cancer.”
-
Opening General Session features findings from RxPONDER, SOFT, RIGHT Choice trials
Read More: Opening General Session features findings from RxPONDER, SOFT, RIGHT Choice trialsTuesday’s General Session included data on race and clinical outcomes in patients with similar 21-gene recurrence scores, the evaluation of the Breast Cancer Index in premenopausal women with early-stage HR-positive breast cancer, and more.
-
Clinical Research Workshop offers key context on timely topics in breast cancer research
Read More: Clinical Research Workshop offers key context on timely topics in breast cancer researchDuring the Tuesday morning session, Thelma Brown, BSc, provided a patient perspective on the importance of increasing knowledge of and access to clinical trials.
-
Basic Science Workshop provides updates on tumor heterogeneity, evolution, and drug resistance
Read More: Basic Science Workshop provides updates on tumor heterogeneity, evolution, and drug resistanceReuben Harris, PhD, explored the effects of the APOBEC protein family on genome evolution in metastatic breast cancer during the session Tuesday morning.
-
Panel to examine the ongoing evolution of antibody drug conjugates in the treatment of breast cancer
Read More: Panel to examine the ongoing evolution of antibody drug conjugates in the treatment of breast cancerIan Krop, MD, PhD, will moderate a Wednesday session examining the current landscape of antibody drug conjugates and what potential they might hold for cancer research and clinical practice.
-
Career Development Forum returns for in-person mentoring
Read More: Career Development Forum returns for in-person mentoringThis roundtable forum on Wednesday will offer early-career scientists a chance to interact with seasoned researchers on 15 different topics.